ArticleBritish journal of cancer2018
Human ex vivo prostate tissue model system identifies ING3 as an oncoprotein.
Article in British journal of cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 35 citations in OpenAlex.
- Prognostic significance of ING3 expression in patients with cancer: A systematic review and meta-analysis.Frontiers in oncology · 2023Pooled it
- Moonlighting role of meiotic SYCP1 in breast cancer: A chromatin-bound regulator of DNA repair, transcription, and drug resistance.Science advances · 2026Article
- Article
- Article
- Decreased Nuclear Immunoexpression of ING3 is a Frequent Event in Lip Carcinogenesis.Head and neck pathology · 2024Article
- The TUDOR domain of SMN is an H3K79Life science alliance · 2023Article
- Experimental in vitro, ex vivo and in vivo models in prostate cancer research.Nature reviews. Urology · 2023Review
- SMA-linked SMN mutants prevent phase separation properties and SMN interactions with FMRP family members.Life science alliance · 2023Article
- Review
- Review
- A Novel Splice Variant of the Inhibitor of Growth 3 Lacks the Plant Homeodomain and Regulates Epithelial-Mesenchymal Transition in Prostate Cancer Cells.Biomolecules · 2021Article
- Overexpression ofExperimental and therapeutic medicine · 2021Article
- ING Proteins: Tumour Suppressors or Oncoproteins.Cancers · 2021Review
- Ex vivo culture of intact human patient derived pancreatic tumour tissue.Scientific reports · 2021Article
- Downregulation of nuclear ING3 expression and translocalization to cytoplasm promotes tumorigenesis and progression in head and neck squamous cell carcinoma (HNSCC).Histology and histopathology · 2020Article
- Focus-ING on DNA Integrity: Implication of ING Proteins in Cell Cycle Regulation and DNA Repair Modulation.Cancers · 2019Review
- Biological Functions of the ING Proteins.Cancers · 2019Review
- ING3 is required for ATM signaling and DNA repair in response to DNA double strand breaks.Cell death and differentiation · 2019Article
- Article
- Patient-derived Models Reveal Impact of the Tumor Microenvironment on Therapeutic Response.European urology oncology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 4 countries.
Funding
Abstract
backgroundAlthough the founding members of the INhibitor of Growth (ING) family of histone mark readers, ING1 and ING2, were defined as tumour suppressors in animal models, the role of other ING proteins in cellular proliferation and cancer progression is unclear.
methodsWe transduced ex vivo benign prostate hyperplasia tissues with inducible lentiviral particles to express ING proteins. Proliferation was assessed by H3S10
resultsWe found that ING3 stimulates cellular proliferation in ex vivo tissues, suggesting that ING3 could be oncogenic. Indeed, ING3 overexpression transformed normal human dermal fibroblasts. We observed elevated levels of ING3 in prostate cancer samples, which correlated with poorer patient survival. Consistent with an oncogenic role, gene-silencing experiments revealed that ING3 is required for the proliferation of breast, ovarian, and prostate cancer cells. Finally, ING3 controls the expression of an intricate network of cell cycle genes by associating with chromatin modifiers and the H3K4
conclusionsOur investigations create a shift in the prevailing view that ING proteins are tumour suppressors and redefine ING3 as an oncoprotein.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.